Navigation Links
The good, the bad and the ugly: The many roles of c-JUN in cancer
Date:6/28/2011

The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumors in both skin and liver. The group of Veronika Sexl at the University of Veterinary Medicine, Vienna, has now uncovered a surprising detail with the discovery an additional function of c-JUN's also prevents silencing of an important anti-tumor factor. The results have recently been published in the open-access journal Oncotarget.

The c-JUN protein was initially described in the late 1980s as the mammalian equivalent of a protein responsible for causing cancer in birds. Intense research in a number of labs has subsequently led to a basic understanding of how the protein works. c-JUN is a transcription factor that modifies (phosphorylates) key regulatory proteins in the cell, thereby activating or deactivating them and leading to unregulated cell division and hence cancer. It has also become clear that c-JUN acts not on its own but in conjunction with an array of further proteins that modulate its function.

Karoline Kollmann in the group of Veronika Sexl, now at the University of Veterinary Medicine, Vienna, recently discovered an additional activity of c-JUN. Together with her collaboration partners at the Medical University of Vienna and in Madrid, she showed that c-JUN can bind to the promoter of a kinase gene, known as Cdk6, thereby preventing the gene from being inactivated (by means of methylation). The result is increased activity of Cdk6, which further stimulates cell division. c-JUN only activates transcription of Cdk6 in cancer cells, where it makes the disease progress even faster. Kollmann's work was published in April in the journal Blood (2011, Vol. 117, pp. 4065-4075).

The surprising aspect of the discovery is that the "new" function of c-JUN is independent of the protein's normal activity. Kollmann has now added a further twist to the tail with the discovery that c-JUN protects not only the Cdk6 gene thereby accelerating tumour formation but also the p16 gene. p16 is a known tumour suppressor gene and its mutation or inactivation is associated with an increased risk of contracting a variety of forms of cancer. By protecting its promoter from inactivation, c-JUN seems to be helping the cells to fight the cancer.

Does this mean that the main villain of the piece is not actually as bad as we thought? Kollmann's response is fairly guarded. "I think it means that the functions of all these proteins are far more complex than we know. They all work together with many other proteins and the overall effect probably depends on a large number of factors. We have a lot more to learn before we can understand what proteins to inhibit to treat the disease."


'/>"/>

Contact: Veronika Sexl
veronika.sexl@vetmeduni.ac.at
43-125-077-2910
University of Veterinary Medicine -- Vienna
Source:Eurekalert

Related medicine news :

1. United Nations Secretary-General Ban Ki-moon, President Bill Clinton, Launch MASSIVEGOOD, a Citizen Solution for Funding Global Health
2. Laughter Not Only Feels Good, Its Good for the Heart
3. Autism Speaks to play key roles at the 2010 International Meeting for Autism Research
4. Do toddlers pick up gender roles during play?
5. Playtime with Parents May Shape Gender Roles
6. The changing roles of 2 hemispheres in stroke recovery
7. 2 proteins play key roles in Burkitts lymphoma
8. Boston University researchers validate important roles of iPSCs in regenerative medicine
9. Enhancing arrest of cell growth to treat cancer in mice
10. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
11. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and ... the issue of world hunger, and shares the simple and achievable answer. “The Land ... and member of the Fairview Missionary Church in Angola, Indiana where he works with ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the ... Congressional political games that circumvent health needs of over 30 million. Many interviews with ... anxieties and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... innovators, engineers, and scientists from around the world, announces the launch of its ... quick and easy portal to research breakthroughs and trending news, vital information on ...
(Date:1/19/2017)... Park City, Utah (PRWEB) , ... January 19, ... ... Sundance Film Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew ... Lounge to provide a condensed version of the clinic’s leading recovery program. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
(Date:1/19/2017)... , January 19, 2017 Shire ... that the U.S. Food and Drug Administration (FDA) has ... New Drug Application (NDA) for SHP465, a long-acting, triple-bead, ... a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The ... around June 20, 2017, the designated Prescription Drug User ...
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
Breaking Medicine Technology: